We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Demand for nanotechnology medical products will grow by more than 17 percent annually to reach $53 billion in 2011, according to a recent report from The Freedonia Group.
The FDA will conduct two studies to investigate how the context and format of risk information in DTC print advertisements influence consumers' understanding of drug risks.
Novartis' first-in-class hypertension treatment Tekturna and
sanofi-aventis' weight-loss drug Acomplia are among several expected 2007 U.S. drug launches that are estimated to reach global blockbuster status, according to IMS Health.
Rep. Henry Waxman (D-Calif.), chairman of the House Oversight and Government Reform Committee, recently sent letters to Boston Scientific and Johnson & Johnson (J&J) asking the firms for information on their drug-eluting stents.
Takeda's television reminder ad for sleep agent Rozerem suggests that the product is indicated for use in children, making the it subject to the regulations of standard DTC advertising, according to a recent warning letter.
Medtronic's implantable cardioverter-defibrillator (ICD) DTC ad campaign helps St. Jude Medical more than it helps Medtronic, according to Lazard Capital Markets.
A bill introduced in the Vermont Senate would allow the state to sue drugmakers for what it calls "unconscionable pricing" of prescription drugs used to treat serious public health problems.
The Prescription Access Litigation Project (PAL) has entered a $24 million settlement with EMD Serono and Merck Serono International to resolve a nationwide classaction lawsuit.
Healthcare spending will continue to grow more quickly than the economy over the next decade as more Americans join government-provided healthcare programs, according to a report from economists at the Centers for Medicare & Medicaid Services (CMS).